Researchers from Stanford have developed an innovative drug capable of reversing age-related joint degeneration. As reported by “Pro Nedra,” the new injection restores damaged cartilage, offering a breakthrough in arthritis treatment. The drug targets the enzyme 15-PGDH, whose activity increases with age, leading to the degradation of joint tissues and the development of osteoarthritis. After the vaccine is administered, the level of this enzyme decreases, and the concentration of beneficial prostaglandin increases, stimulating the growth of new cartilage to replace damaged tissue. Experiments on elderly mice showed a threefold increase in cartilage thickness, and human trials confirmed the successful renewal of its structure to the state of young, healthy tissue. The drug is currently undergoing clinical trials. Particularly promising were the results on injury models similar to anterior cruciate ligament (ACL) damage, which often leads to severe joint diseases. The medication eliminates signs of degeneration, offering hope to millions of people for relief from joint wear and tear problems without surgical intervention or expensive implants.
About the Author
